Weaning of inhaled nitric oxide: is there a best strategy?
Background: Inhaled nitric oxide (iNO) has been used in the treatment of pulmonary hypertension in neonates for many years. iNO was approved by the FDA in 1999 for hypoxic respiratory failure (HRF) in term and near term infants, defined as > 34 weeks gestational age (GA). iNO is used for persiste...
Saved in:
Main Authors: | Anita M. Ware (Author), Sergio G. Golombek (Author) |
---|---|
Format: | Book |
Published: |
Hygeia Press di Corridori Marinella,
2015-04-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Novel use of riociguat in infants with severe pulmonary arterial hypertension unable to wean from inhaled nitric oxide
by: L. T. Domingo, et al.
Published: (2022) -
A Comparative Study of Inhaled Nitric Oxide and an Intravenously Administered Nitric Oxide Donor in Acute Pulmonary Hypertension
by: Stene Hurtsén A, et al.
Published: (2020) -
Beyond the inhaled nitric oxide in persistent pulmonary hypertension of the newborn
by: Mei-Yin Lai, et al.
Published: (2018) -
Inhaled Nitric Oxide Counterbalances ET-1 Dependent Pulmonary Hypertension and Bronchoconstriction in the Pig
by: M. G. Clement, et al.
Published: (1994) -
Use of inhaled nitric oxide in pediatric cardiac intensive care unit
by: Erkut Öztürk, et al.
Published: (2016)